{"id":5539,"date":"2018-06-30T13:44:00","date_gmt":"2018-06-30T13:44:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&p=5539"},"modified":"2024-05-02T11:19:19","modified_gmt":"2024-05-02T09:19:19","slug":"combination-therapy-with-cytapheresis-plus-vedolizumab-in-a-corticosteroid-dependent-patient-with-ulcerative-colitis-and-previous-anti-tnf-drug-failure","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/es\/professional\/scientific-corner\/combination-therapy-with-cytapheresis-plus-vedolizumab-in-a-corticosteroid-dependent-patient-with-ulcerative-colitis-and-previous-anti-tnf-drug-failure\/","title":{"rendered":"Combination therapy with cytapheresis plus vedolizumab in a corticosteroid-dependent patient with ulcerative colitis and previous ANTI-TNF-drug failure"},"content":{"rendered":"
\n

Esteban S\u00e1ez-Gonz\u00e1lez<\/a> 1<\/a><\/sup>, Mariam Aguas<\/a> 2<\/a><\/sup>, Jos\u00e9 M Huguet<\/a> 3<\/a><\/sup>, Pilar Nos<\/a> 4<\/a><\/sup>, Bel\u00e9n Beltr\u00e1n<\/a> 2<\/a><\/sup> , Dig Liver Dis. 2018 Apr;50(4):415-417.<\/p>\n<\/div>\n\n

\n

We have reported the first case of using GMA in combination with vedolizumab in a patient with active, steroid-dependent UC with an inadequate response to vedolizumab and previous biologic failure to adalimumab and infliximab, achieving remission in the follow-up. It is believed that the primary consequence of GMA therapy is a selective depletion of certain subsets of myeloid leucocytes, the most relevant of which could be the CD14+ CD16+ DR++phenotype, also known as the proinflammatory monocytes.This selective depletion of circulating leucocytes could enhance the reduction of gut trafficking of leucocytes induced by vedolizumab and modify the concentration of proinflammatory cytokines. In this clinical context, GMA therapy could be a safe, on pharmacological treatment that could help to reduce the inflammatory load, thereby enhancing the effect of biologic drugs.<\/p>\n<\/div>\n\n

\n

https:\/\/pubmed.ncbi.nlm.nih.gov\/29397323\/<\/a><\/p>\n<\/div>\n\n

\n

https:\/\/www.dldjournalonline.com\/article\/S1590-8658(18)30138-5\/fulltext<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Esteban S\u00e1ez-Gonz\u00e1lez 1, Mariam Aguas 2, Jos\u00e9 M Huguet 3, Pilar Nos 4, Bel\u00e9n Beltr\u00e1n 2 , Dig Liver Dis. 2018 Apr;50(4):415-417. We have reported the first case of using GMA in combination with vedolizumab in a patient with active, steroid-dependent UC with an inadequate response to vedolizumab and previous biologic failure to adalimumab and infliximab, achieving remission in the follow-up. It is believed […]<\/p>\n","protected":false},"template":"","scientific_tags":[353,303,55,306,66],"class_list":["post-5539","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-biologic-refractory","scientific_tags-combination","scientific_tags-steroid-dependent","scientific_tags-ulcerative-colitis","scientific_tags-vedolizumab"],"acf":[],"yoast_head":"\nCombination therapy with cytapheresis plus vedolizumab in a corticosteroid-dependent patient with ulcerative colitis and previous ANTI-TNF-drug failure - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/combination-therapy-with-cytapheresis-plus-vedolizumab-in-a-corticosteroid-dependent-patient-with-ulcerative-colitis-and-previous-anti-tnf-drug-failure\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Combination therapy with cytapheresis plus vedolizumab in a corticosteroid-dependent patient with ulcerative colitis and previous ANTI-TNF-drug failure - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Esteban S\u00e1ez-Gonz\u00e1lez 1, Mariam Aguas 2, Jos\u00e9 M Huguet 3, Pilar Nos 4, Bel\u00e9n Beltr\u00e1n 2 , Dig Liver Dis. 2018 Apr;50(4):415-417. We have reported the first case of using GMA in combination with vedolizumab in a patient with active, steroid-dependent UC with an inadequate response to vedolizumab and previous biologic failure to adalimumab and infliximab, achieving remission in the follow-up. It is believed […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/combination-therapy-with-cytapheresis-plus-vedolizumab-in-a-corticosteroid-dependent-patient-with-ulcerative-colitis-and-previous-anti-tnf-drug-failure\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-02T09:19:19+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/combination-therapy-with-cytapheresis-plus-vedolizumab-in-a-corticosteroid-dependent-patient-with-ulcerative-colitis-and-previous-anti-tnf-drug-failure\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/combination-therapy-with-cytapheresis-plus-vedolizumab-in-a-corticosteroid-dependent-patient-with-ulcerative-colitis-and-previous-anti-tnf-drug-failure\/\",\"name\":\"Combination therapy with cytapheresis plus vedolizumab in a corticosteroid-dependent patient with ulcerative colitis and previous ANTI-TNF-drug failure - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2018-06-30T13:44:00+00:00\",\"dateModified\":\"2024-05-02T09:19:19+00:00\",\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/combination-therapy-with-cytapheresis-plus-vedolizumab-in-a-corticosteroid-dependent-patient-with-ulcerative-colitis-and-previous-anti-tnf-drug-failure\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Combination therapy with cytapheresis plus vedolizumab in a corticosteroid-dependent patient with ulcerative colitis and previous ANTI-TNF-drug failure - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/combination-therapy-with-cytapheresis-plus-vedolizumab-in-a-corticosteroid-dependent-patient-with-ulcerative-colitis-and-previous-anti-tnf-drug-failure\/","og_locale":"es_ES","og_type":"article","og_title":"Combination therapy with cytapheresis plus vedolizumab in a corticosteroid-dependent patient with ulcerative colitis and previous ANTI-TNF-drug failure - Adacyte","og_description":"Esteban S\u00e1ez-Gonz\u00e1lez 1, Mariam Aguas 2, Jos\u00e9 M Huguet 3, Pilar Nos 4, Bel\u00e9n Beltr\u00e1n 2 , Dig Liver Dis. 2018 Apr;50(4):415-417. We have reported the first case of using GMA in combination with vedolizumab in a patient with active, steroid-dependent UC with an inadequate response to vedolizumab and previous biologic failure to adalimumab and infliximab, achieving remission in the follow-up. It is believed […]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/combination-therapy-with-cytapheresis-plus-vedolizumab-in-a-corticosteroid-dependent-patient-with-ulcerative-colitis-and-previous-anti-tnf-drug-failure\/","og_site_name":"Adacyte","article_modified_time":"2024-05-02T09:19:19+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/combination-therapy-with-cytapheresis-plus-vedolizumab-in-a-corticosteroid-dependent-patient-with-ulcerative-colitis-and-previous-anti-tnf-drug-failure\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/combination-therapy-with-cytapheresis-plus-vedolizumab-in-a-corticosteroid-dependent-patient-with-ulcerative-colitis-and-previous-anti-tnf-drug-failure\/","name":"Combination therapy with cytapheresis plus vedolizumab in a corticosteroid-dependent patient with ulcerative colitis and previous ANTI-TNF-drug failure - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2018-06-30T13:44:00+00:00","dateModified":"2024-05-02T09:19:19+00:00","inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/combination-therapy-with-cytapheresis-plus-vedolizumab-in-a-corticosteroid-dependent-patient-with-ulcerative-colitis-and-previous-anti-tnf-drug-failure\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner\/5539","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/media?parent=5539"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific_tags?post=5539"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}